ACRO Biomedical Co., Ltd. (6748) - Net Assets
Based on the latest financial reports, ACRO Biomedical Co., Ltd. (6748) has net assets worth NT$581.44 Million TWD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$607.52 Million) and total liabilities (NT$26.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$581.44 Million |
| % of Total Assets | 95.71% |
| Annual Growth Rate | 37.91% |
| 5-Year Change | 251.03% |
| 10-Year Change | N/A |
| Growth Volatility | 77.72 |
ACRO Biomedical Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how ACRO Biomedical Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACRO Biomedical Co., Ltd. (2019–2024)
The table below shows the annual net assets of ACRO Biomedical Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$626.28 Million | -8.72% |
| 2023-12-31 | NT$686.08 Million | +81.21% |
| 2022-12-31 | NT$378.61 Million | +191.20% |
| 2021-12-31 | NT$130.02 Million | -27.12% |
| 2020-12-31 | NT$178.41 Million | +42.21% |
| 2019-12-31 | NT$125.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ACRO Biomedical Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 960700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$612.18 Million | 97.75% |
| Other Comprehensive Income | NT$-588.00K | -0.09% |
| Other Components | NT$251.39 Million | 40.14% |
| Total Equity | NT$626.28 Million | 100.00% |
ACRO Biomedical Co., Ltd. Competitors by Market Cap
The table below lists competitors of ACRO Biomedical Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
|
$150.39 Million |
|
Naturhouse Health SA
MC:NTH
|
$150.47 Million |
|
Global Dividend Growth Split Corp Class A
TO:GDV
|
$150.52 Million |
|
Nekkar Asa
OL:NKR
|
$150.52 Million |
|
Carmel Corp Ltd.
TA:CRML
|
$150.33 Million |
|
Shanghai Jinjiang International Travel Co Ltd
SHG:900929
|
$150.32 Million |
|
Venus Remedies Limited
NSE:VENUSREM
|
$150.28 Million |
|
Votum SA
WAR:VOT
|
$150.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACRO Biomedical Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 686,081,000 to 626,276,000, a change of -59,805,000 (-8.7%).
- Net loss of 62,088,000 reduced equity.
- Other comprehensive income increased equity by 890,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-62.09 Million | -9.91% |
| Other Comprehensive Income | NT$890.00K | +0.14% |
| Other Changes | NT$1.39 Million | +0.22% |
| Total Change | NT$- | -8.72% |
Book Value vs Market Value Analysis
This analysis compares ACRO Biomedical Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.19x to 6.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$4.14 | NT$67.00 | x |
| 2020-12-31 | NT$5.89 | NT$67.00 | x |
| 2021-12-31 | NT$3.66 | NT$67.00 | x |
| 2022-12-31 | NT$7.99 | NT$67.00 | x |
| 2023-12-31 | NT$13.09 | NT$67.00 | x |
| 2024-12-31 | NT$10.19 | NT$67.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACRO Biomedical Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -140.37%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.05x
- Recent ROE (-9.91%) is above the historical average (-19.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -28.04% | -277.37% | 0.09x | 1.14x | NT$-67.86 Million |
| 2021 | -39.05% | -232.61% | 0.14x | 1.16x | NT$-63.78 Million |
| 2022 | -16.08% | -220.33% | 0.07x | 1.05x | NT$-98.74 Million |
| 2023 | -6.04% | -81.11% | 0.07x | 1.04x | NT$-110.03 Million |
| 2024 | -9.91% | -140.37% | 0.07x | 1.05x | NT$-124.72 Million |
Industry Comparison
This section compares ACRO Biomedical Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,540,359,700
- Average return on equity (ROE) among peers: 6.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACRO Biomedical Co., Ltd. (6748) | NT$581.44 Million | -28.04% | 0.04x | $150.33 Million |
| Synbio Tech Inc. (1295) | $758.45 Million | 17.38% | 0.83x | $189.03 |
| Apex Biotechnology Corp (1733) | $1.68 Billion | 6.79% | 0.68x | $94.31 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.72 Billion | 9.84% | 0.66x | $192.35 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $175.58 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.68 Billion | 10.48% | 0.80x | $71.97 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $99.47 Million |
| Level Biotechnology (3118) | $529.43 Million | 10.96% | 0.46x | $34.20 Million |
| GenMont Biotech Inc (3164) | $837.28 Million | 3.69% | 0.64x | $48.64 Million |
| Medigen Biotechnology (3176) | $2.69 Billion | -9.52% | 0.80x | $137.81 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $131.73 Million |
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.